tiprankstipranks
Pharvaris (PHVS)
NASDAQ:PHVS
US Market
PHVS
Pharvaris
RESEARCH TOOLSreports

Pharvaris (PHVS) Stock News & Sentiment

167 Followers
Pharvaris: Late-Stage Deucrictibant Progress, Expansion into Untreated Angioedema Markets, and Solid Cash Runway Underpin Buy Rating and $60 Target
Premium
Ratings
Pharvaris: Late-Stage Deucrictibant Progress, Expansion into Untreated Angioedema Markets, and Solid Cash Runway Underpin Buy Rating and $60 Target
3d ago
PHVS
Pharvaris Posts 2025 Results as Deucrictibant Nears NDA Filing and Key Phase 3 Data
Premium
Company Announcements
Pharvaris Posts 2025 Results as Deucrictibant Nears NDA Filing and Key Phase 3 Data
8d ago
6K
PHVS
Pharvaris: Multiple Late‑Stage Catalysts, Differentiated Oral HAE Franchise, and Solid Cash Runway Support Buy Rating and $48 Target
Premium
Ratings
Pharvaris: Multiple Late‑Stage Catalysts, Differentiated Oral HAE Franchise, and Solid Cash Runway Support Buy Rating and $48 Target
3M ago
PHVS
Pharvaris Sets 2026 Roadmap as Deucrictibant Advances Toward NDA Filing and Phase 3 Readouts
Premium
Company Announcements
Pharvaris Sets 2026 Roadmap as Deucrictibant Advances Toward NDA Filing and Phase 3 Readouts
3M ago
6K
PHVS
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
Premium
Market News
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
4M ago
IMNM
KYTX
Pharvaris’s Deucrictibant: Promising Efficacy Amidst Uncertain Market Prospects
Premium
Ratings
Pharvaris’s Deucrictibant: Promising Efficacy Amidst Uncertain Market Prospects
4M ago
PHVS
Pharvaris’ Deucrictibant Shows Promising Efficacy and Safety in RAPIDe-3 Study, Analyst Sets Buy Rating with Increased Price Target
Premium
Ratings
Pharvaris’ Deucrictibant Shows Promising Efficacy and Safety in RAPIDe-3 Study, Analyst Sets Buy Rating with Increased Price Target
4M ago
PHVS
More PHVS News >

PHVS News on the Web

Texas Instruments upgraded, Circle downgraded: Wall Street’s top analyst calls
TipRanks News
Neutral
Analysts Offer Insights on Healthcare Companies: Avita Medical (RCEL) and Pharvaris (PHVS)
TipRanks News
Neutral
Pharvaris initiated with an Outperform at Wolfe Research
TipRanks News
Bullish
Morgan Stanley Sticks to Their Buy Rating for Pharvaris (PHVS)
TipRanks News
Bullish
Pharvaris price target raised to $42 from $41 at Wedbush
TipRanks News
Bullish
Pharvaris: Late-Stage Deucrictibant Progress, Expansion into Untreated Angioedema Markets, and Solid Cash Runway Underpin Buy Rating and $60 Target
TipRanks News
Bullish
Pharvaris price target lowered to $51 from $52 at RBC Capital
TipRanks News
Bullish
Analysts Are Bullish on Top Healthcare Stocks: Medtronic (MDT), Pharvaris (PHVS)
TipRanks News
Bullish

News Score - Last 7 Days

Very Positive
PHVS
Sector Average
Media Buzz
This Week8 articles
Weekly Average3.5 articles
News Sentiment
This Week100%
Sector Average69%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is PHVS’s Media Buzz Sentiment?
8 articles about PHVS were published this week. In an average week, 3.5 articles are published.
    What is PHVS’s weekly average amount of articles?
    In an average week, 3.5 articles about PHVS are published.
      What is PHVS’s News Sentiment?
      100% of articles about PHVS were positive this week, compared to its sector average of 69%.
        Healthcare Stocks that are Trending in the News
        NBIXNeurocrine
        STAAStaar Surgical
        AORTArtivion
        OWLTOwlet
        HUMHumana
        Showing the stocks with the most bullish news sentiment over the past week